Acute myeloid leukemia secondary to acute B lymphoblastic leukemia treated with maintenance therapy in a child: A
Xiaoning Wang1, Ding Ding2, Yalin Liu1
1Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
Background:
Acute lymphoblastic leukemia (ALL) has the highest incidence among childhood hematologic cancers. Exposure to certain cytotoxic therapies for ALL is correlated with a higher risk of secondary malignancies.
Case:
We report a rare case of a 6-year-old girl being diagnosed with secondary acute myeloid leukemia (AML) during her maintenance phase of treatment for ALL with TEL-AML1 fusion gene, approximately 17 months after the primary diagnosis.
Conclusion:
This case indicates that we should recognize the increased risk of secondary AML for pediatric ALL patients with TEL-AML1 fusion gene if multiple alkylating drugs and inhibitors for topoisomerase II are included in induction chemotherapy.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
